Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri

NCT03399981 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03399981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03399981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
June 1, 2017
Completion date
December 31, 2023
Enrollment
80,327 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

progressive multifocal leukoencephalopathy